The HIV proteinase - A target for antiviral therapy;HIVS PROTEINASE - ET MAAL FOR ANTIVIRALE MIDLER

Tidsskrift for den Norske Laegeforening

Volumn 116, Issue 24, 1996, Pages 2908-2911

  Grinde, Bjørn ^a   Jonassen, Tom Øystein ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE; PROTEINASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOTECHNOLOGY; DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SHORT SURVEY; UNITED STATES; CHEMICAL STRUCTURE; CHEMISTRY; PHYSIOLOGY; REVIEW;

ANTIVIRAL AGENTS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR STRUCTURE;

EID: 0030578987     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (20)

1. Kay J, Dunn BM. Viral proteinases: weakness in strength. Biochim Biophys Acta 1990; 1048: 1-18.
2. West ML, Fairlie DP. Targeting HIV-1 protease: a test of drugdesign methodologies. TIPS 1995; 16: 67-75.
3. Skalka AM. Retroviral proteases: first glimpses at the anatomy of a processing machine. Cell 1989; 56: 911-3.
4. Haseltine WA, Wong-Staal F. The molecular biology of the AIDS virus. Sci Am 1988 259: 52-8.
5. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4185-9.
6. Gottlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristylation in morphogenesis and infectivity of human immunodeficincy virus type 1. Proc Natl Acad Sci USA 1989; 86: 5781-5.
7. Wlodawer A, Miller M, Jaskolski M, Sathyanarayana BK, Baldwin E, Weber IT et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989; 245: 616-21.
8. Grinde B, Hungnes O, Tjøtta E. The proteinase inhibitor pepstatin A inhibits formation of reverse transcriptase in H9 cells infected with human immunodefficiency virus 1. AIDS Res Human Retro 1989; 5: 269-74.
9. Gait MJ, Karn J. Progress in anti-HIV structure-based drug design. Tibtech 1995; 13: 430-8.
10. Wlodawer A. Rational drug design: the proteinase inhibitors. Pharmacotherapy 1994; 14 (suppl): 9-20.
11. Grinde B, Cameron CE, Leis J, Weber I, Wlodawer A, Burstein H et al. Mutations that alter the activity of the Rous sarcoma virus protease. J Biol Chem 1992; 267: 9481-90.
12. Grinde B, Cameron CE, Leis J, Weber I, Wlodawer A, Burstein H et al. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J Biol Chem 1992; 267: 9491-8.
13. Cameron CE, Grinde B, Jentoft J, Leis J, Weber I, Copeland TD et al. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins. J Biol Chem 1992; 267: 23735-41.
14. Cameron CE, Grinde B, Jacques P, Jentoft J, Leis J, Wlodawer A et al. Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases. J Biol Chem 1993; 268: 11711-20.
15. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952-5.
16. Barnett AA. Protease inhibitors fly through FDA. Lancet 1996; 347: 678.
17. Danner SA, Carr A, Leonard JM, Lehman LM, Guidol F, Gonzales J et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33.
18. Borman AM, Paulous S, Clavel F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 1996; 77: 419-26.
19. Richman DD. Protease uninhibited. Nature 1995; 374: 494.
20. Jong MD, Boucher CAB, Galasso GJ, Hirsch MS, Kern ER, Lange JMA et al. Consensus symposium on combined antiviral therapy. Antiviral Res 1996; 29: 5-30.